Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE6D | O43924 | 1/20 | 0.39 |
| ▸ | PDE8A | O60658 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | PDE6A | P16499 | 1/20 | 0.39 |
| ▸ | PDE6G | P18545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927587 | 0.72 | NUDT1 (0.48) | NUDT1PARP1METAP1METAP2DAO | |
| Bromide SCHEMBL28646392 | 0.71 | NUDT1 (0.47) | NUDT1PARP1METAP1METAP2DAO | |
| SCHEMBL21389521 | 0.69 | NUDT1 (0.60) | NUDT1METAP1METAP2PDE5AAURKA | |
| SCHEMBL323981 | 0.69 | NUDT1 (0.60) | NUDT1METAP1METAP2PDE5AFGFR1 | |
| SCHEMBL491810 | 0.69 | PARP1 (0.42) | NUDT1PARP1METAP1METAP2PDE5A | |
| SCHEMBL5413200 | 0.69 | PARP1 (0.42) | NUDT1PARP1METAP1METAP2PDE5A | |
| SCHEMBL7977958 | 0.69 | NUDT1 (0.46) | NUDT1PARP1METAP1METAP2DAO | |
| SCHEMBL29376620 | 0.68 | — | — | |
| SCHEMBL40861 | 0.68 | — | — | |
| SCHEMBL1170747 | 0.68 | METAP1 (0.72) | NUDT1METAP1METAP2PDE5AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049503-B1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | AMGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7935709-B2 | 2-quinazolinone compounds and methods of use | AMGEN INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7928106-B2 | 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928106-B2 | 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101641358-A | Aza-pyridopyrimidinone derivatives | HOFFMANN LA ROCHE CH | 2010-02-03 | — | — | CN | disclosed |
| CN-101641358-A | Aza-pyridopyrimidinone derivatives | HOFFMANN LA ROCHE CH | 2010-02-03 | — | — | CN | disclosed |
| CN-101641358-A | Aza-pyridopyrimidinone derivatives | HOFFMANN LA ROCHE CH | 2010-02-03 | — | — | CN | disclosed |
| EP-2139895-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2139895-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2049503-A1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | Amgen Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008116742-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116742-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | AMGEN INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2008011032-A1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | MAP3K1, MAP3K2, MAP3K7 | NUDT1 1584/4885PARP1 798/4885METAP1 2700/4885 |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | CHRM1, CHRM2, CHRM4 | NUDT1 1025/4885PARP1 1443/4885METAP1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.